Astellas Completes Acquisition of Audentes Therapeutics

Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics, Inc. (“Audentes”), through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition Corp. (“Asilomar”) for all of the issued and outstanding shares of common stock of Audentes for a price of US$60.00 per share net to the seller in cash (“Tender Offer”) and the subsequent merger of Asilomar with and into Audentes. The acquisition positions the combined company to become a global leader in AAV-based genetic medicines.

Read the full article: Astellas Completes Acquisition of Audentes Therapeutics //

Source: https://www.prnewswire.com/news-releases/astellas-completes-acquisition-of-audentes-therapeutics-300987461.html

Scroll to Top